HSCT offers a transformative approach for select patients with refractory SSc, SLE, RA, DADA2, ANCA-associated vasculitis, TA, and JIA, achieving long-term, drug-free remission in some. Future research should optimize conditioning protocols, refine patient selection, and assess long-term outcomes to maximize HSCT benefits and minimize risks.
Suresh et al. (Sun,) studied this question.